Study of BB-031 in Acute Ischemic Stroke Patients (RAISE)

PHASE2RecruitingINTERVENTIONAL
Enrollment

156

Participants

Timeline

Start Date

July 31, 2024

Primary Completion Date

June 30, 2027

Study Completion Date

September 30, 2027

Conditions
Acute Ischemic Stroke
Interventions
DRUG

BB-031

Solution for injection

DRUG

Placebo

0.9% sodium chloride for injection

Trial Locations (19)

2305

RECRUITING

John Hunter Hospital, New Lambton Heights

3050

RECRUITING

The Royal Melbourne Hospital, Parkville

3168

RECRUITING

Monash Medical Centre, Clayton

4102

RECRUITING

Princess Alexandra Hospital, Woolloongabba

5000

RECRUITING

Royal Adelaide Hospital, Adelaide

6150

RECRUITING

Fiona Stanley Hospital, Murdoch

27610

NOT_YET_RECRUITING

WakeMed, Raleigh

32207

RECRUITING

Baptist Health Medical Center, Jacksonville

43210

RECRUITING

The Ohio State University, Columbus

43604

RECRUITING

ProMedica Toledo Hospital, Toledo

48202

RECRUITING

Henry Ford Hospital, Detroit

78550

NOT_YET_RECRUITING

Valley Baptist Medical Center - Harlingen, Harlingen

85251

ACTIVE_NOT_RECRUITING

HonorHealth Bob Bove Neuroscience Institute, Scottsdale

90503

NOT_YET_RECRUITING

Providence Little Company of Mary Medical Center, Torrance

90806

WITHDRAWN

MemorialCare Long Beach Medical Center, Long Beach

94010

WITHDRAWN

Mills Peninsula Medical Center, Burlingame

94109

WITHDRAWN

California Pacific Medical Center, San Francisco

T2N2T9

RECRUITING

University of Calgary, Calgary

T6G 2G3

RECRUITING

University of Alberta Hospital, Edmonton

Sponsors
All Listed Sponsors
lead

Basking Biosciences, Inc.

INDUSTRY

NCT06226805 - Study of BB-031 in Acute Ischemic Stroke Patients (RAISE) | Biotech Hunter | Biotech Hunter